Physician profile
Samuel H Klatman
NPI 1144616970
$49,678.24
in general payments reported to CMS, 2019-2025
20 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24K · 2021: $19K · 2022: $4,561 · 2023: $892 · 2024: $532 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $23,684.22 | 2020-2022 | |
| Smith+Nephew, INC. | $8,430.34 | 2020-2025 | Katalyst Bipolar Radial Head System, Aetos Shoulder System, Evos |
| Impactortho, INC. | $7,200.00 | 2021-2022 | |
| Djo, LLC | $5,000.00 | 2020-2021 | |
| Elevate Surgical Co | $2,778.85 | 2022-2024 | |
| Stryker Corporation | $1,187.65 | 2020-2023 | Inspace, Variax |
| Sanara Medtech INC. | $197.37 | 2021-2022 | |
| Acumed LLC | $162.17 | 2023-2024 | Acumed |
| Miach Orthopaedics, INC. | $136.72 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $133.84 | 2021-2025 | Exparel |
| Breg, INC | $127.79 | 2022 | |
| Nevro Corp. | $118.21 | 2022 | |
| Boston Scientific Corporation | $115.71 | 2022 | |
| Linvatec Corporation | $112.30 | 2023 | Biobrace 23mm |
| Bioventus LLC | $90.79 | 2022-2025 | Supartz Fx Sodium Hyaluronate, Xcell, Durolane |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molnlycke Health Care US, LLC | $75.42 | 2024 | Avance, Mepilex Ag |
| Depuy Synthes Sales INC. | $51.48 | 2020-2021 | |
| Fidia Pharma USA INC. | $36.39 | 2024 | Hymovis, Triluron, Hyalgan |
| Vericel Corporation | $21.37 | 2022 | |
| Solventum Corporation | $17.62 | 2025 | V.A.C. Veraflo, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Klatman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.